A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non–small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non–small cell lung cancer and triple-negative breast cancer.
Institut(e)Unit for Clinical Pharmacology (KKG-EKLiP)
FörderungenThe m4 Award of the Bavarian Ministry for Economic Affairs Bavarian Research Foundation (BAYCELLATOR) Go-Bio-Initiative Monika Kutzner Foundation for Cancer Research Institutional Strategy LMUexcellent of LMU Munich Hector Foundation Ernst Jung Stiftung Wilhelm-Sander-Stiftung German Cancer Aid (AvantCAR.de) Else Kroener-Fresenius-Stiftung (IOLIN) Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer by European Union Melanoma Research Alliance Elite Network of Bavaria Deutsche Forschungsgemeinschaft Bruno and Helene Joester Foundation (360degrees CAR) Bundesministerium fuer Bildung und Forschung European Research Council
Deutsche Jose Carreras Leukaemie Stiftung SFB-TRR-Fritz-Bender Foundation Bavarian Cancer Research Center (TANGO)